BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36155113)

  • 21. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
    Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
    Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of Deep Learning Analysis for the Diagnosis of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Kuwahara T; Hara K; Mizuno N; Okuno N; Matsumoto S; Obata M; Kurita Y; Koda H; Toriyama K; Onishi S; Ishihara M; Tanaka T; Tajika M; Niwa Y
    Clin Transl Gastroenterol; 2019 May; 10(5):1-8. PubMed ID: 31117111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis.
    Wang W; Zhang L; Chen L; Wei J; Sun Q; Xie Q; Zhou X; Zhou D; Huang P; Yang Q; Xie H; Zhou L; Zheng S
    Biomed Rep; 2015 Jan; 3(1):43-50. PubMed ID: 25469245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients.
    Adsay NV; Conlon KC; Zee SY; Brennan MF; Klimstra DS
    Cancer; 2002 Jan; 94(1):62-77. PubMed ID: 11815961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology, Carcinoembryonic Antigen, and Amylase in Intraductal Papillary Mucinous Neoplasm.
    Moris M; Raimondo M; Woodward TA; Skinner V; Arcidiacono PG; Petrone MC; De Angelis C; Manfrè S; Fusaroli P; Asbun H; Stauffer J; Wallace MB
    Pancreas; 2016 Jul; 45(6):870-5. PubMed ID: 26646270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
    Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
    Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    Ann Surg; 2012 Mar; 255(3):517-22. PubMed ID: 22301608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.
    Hwang DW; Jang JY; Lee SE; Lim CS; Lee KU; Kim SW
    Langenbecks Arch Surg; 2012 Jan; 397(1):93-102. PubMed ID: 20640860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of aggressive surgery for an invasive carcinoma derived from an intraductal papillary mucinous neoplasm diagnosed preoperatively as borderline resectable.
    Aimoto T; Mizutani S; Kawano Y; Suzuki H; Uchida E
    J Nippon Med Sch; 2013; 80(5):371-7. PubMed ID: 24189355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Kucera S; Centeno BA; Springett G; Malafa MP; Chen YA; Weber J; Klapman J
    JOP; 2012 Jul; 13(4):409-13. PubMed ID: 22797397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
    Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy.
    Polk SL; Choi JW; McGettigan MJ; Rose T; Ahmed A; Kim J; Jiang K; Balagurunathan Y; Qi J; Farah PT; Rathi A; Permuth JB; Jeong D
    World J Gastroenterol; 2020 Jun; 26(24):3458-3471. PubMed ID: 32655269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
    Ishida M; Egawa S; Aoki T; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Unno M; Moriya T; Horii A; Furukawa T
    Pancreas; 2007 Nov; 35(4):348-52. PubMed ID: 18090241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
    Hoffman DH; Ream JM; Hajdu CH; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Apr; 42(4):1222-1228. PubMed ID: 27900458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
    Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
    Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study.
    Yamada T; Minami T; Yamada M; Terauchi Y
    Endocr J; 2023 Nov; 70(11):1069-1075. PubMed ID: 37690842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.